Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values

Area of Science:

• Urology
• Oncology
• Diagnostic Medicine

Background:

• Prostate cancer screening relies on prostate-specific antigen (PSA) levels and digital rectal exams.
• Initial negative prostate biopsies do not always rule out cancer, necessitating further investigation.

Purpose of the Study:

• To assess the necessity and yield of repeat prostate biopsies in men with an initial negative biopsy but persistent elevated PSA.
• To determine the optimal number of repeat biopsies for detecting prostate cancer.

Main Methods:

• A longitudinal study evaluated 1,136 men undergoing serial prostate biopsies based on PSA levels (>4.0 ng/mL) and abnormal findings.
• Cancer detection rates were analyzed across initial and subsequent biopsies (biopsy 2, 3, 4+).
• Median PSA levels and rate of change were compared between men with and without detected cancer.

Main Results:

• 34% of initial biopsies detected cancer. Of those with negative initial biopsies but persistent PSA elevation, 19% had cancer on biopsy 2, 8% on biopsy 3, and 7% on biopsy 4+.
• 96% of all detected prostate cancers were identified by the first or second biopsy.
• Men with detected cancer had significantly higher median initial PSA, follow-up PSA, and PSA rate of change.

Conclusions:

• Men with persistently elevated PSA after a negative initial prostate biopsy should undergo at least one repeat biopsy.
• Repeat biopsies are essential for adequate exclusion of detectable prostate cancer in screening protocols.
• Early detection through serial biopsies may correlate with a higher rate of organ-confined tumors.